Akcea Therapeutics, Inc. (AKCA): Price and Financial Metrics
AKCA Price/Volume Stats
Current price | $18.17 | 52-week high | $21.70 |
Prev. close | $18.14 | 52-week low | $8.00 |
Day low | $18.13 | Volume | 815,300 |
Day high | $18.17 | Avg. volume | 361,806 |
50-day MA | $15.31 | Dividend yield | N/A |
200-day MA | $15.48 | Market Cap | 1.85B |
AKCA Stock Price Chart Interactive Chart >
Akcea Therapeutics, Inc. (AKCA) Company Bio
Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Latest AKCA News From Around the Web
Below are the latest news stories about Akcea Therapeutics Inc that investors may wish to consider to help them evaluate AKCA as an investment opportunity.
Akcea's Waylivra secures NICE recommendation for ultra-rare inherited disorderAkcea Therapeutics (AKCA), majority-owned affiliate of Ionis Pharmaceuticals (IONS), announces that the National Institute for Health and Care Excellence ((NICE)) has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for the treatment of Familial Chylomicronaemia Syndrome ((FCS)) for routine care on the National Health Service in England.FCS is a rare, inherited disorder characterised... |
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in EnglandLONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Evaluation Document (FED) for volanesorsen for the treatment of Familial Chylomicronaemia Syndrome (FCS) for routine care on the National Health Service (NHS) in England. FCS is an under-recognised condition characterised by extremely high triglycerides levels (10 to 100 times no |
Akcea shoots up 59% on positive vupanorsen data; Ionis acquires remaining stake for $500MAkcea Therapeutics (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals (IONS) presents data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) at the ESC Congress 2020.Vupanorsen, an investigational antisense therapy being developed using Ionis' LIgand Conjugated Antisense technology platform to reduce the production of angiopoietin-like 3 (ANGPTL3) protein from the liver which is... |
Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining StakeAkcea Therapeutics Inc (NASDAQ: AKCA ) shares were rallying strongly Monday following a buyout deal. The Ionis, Akcea Deal Terms: Akcea and its majority owner Ionis Pharmaceuticals Inc (NASDAQ: IONS ) announced a definitive agreement under which Ionis will acquire the 24% stake in Akcea it does not already own for $18.15 per share — about 60% higher than Akcea's Friday closing price. The total transaction value is about $500 million. The deal has been approved by the boards of both companies and … Full story available on Benzinga.com |
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with PolyneuropathyAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband der Österreichischen Sozialversicherungsträger, or DV) has granted approval for the national reimbursement of TEGSEDI® (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis. |
AKCA Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | N/A |
5-year | -35.86% |
YTD | N/A |
2023 | N/A |
2022 | N/A |
2021 | N/A |
2020 | 0.00% |
2019 | -43.80% |
Continue Researching AKCA
Want to do more research on Akcea Therapeutics Inc's stock and its price? Try the links below:Akcea Therapeutics Inc (AKCA) Stock Price | Nasdaq
Akcea Therapeutics Inc (AKCA) Stock Quote, History and News - Yahoo Finance
Akcea Therapeutics Inc (AKCA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...